References
Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005;295:405–18.
Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988;171:45–50.
Novicki TJ, Daly JA, Mottice SL, Carroll KC. Comparison of sorbitol MacConkey agar and a two-step method which utilizes enzyme-linked immunosorbent assay toxin testing and a chromogenic agar to detect and isolate enterohemorrhagic Escherichia coli. J Clin Microbiol. 2000;38:547–51.
Fratamico PM, Sackitey SK, Wiedmann M, Deng MY. Detection of Escherichia coli O157:H7 by multiplex PCR. J Clin Microbiol. 1995;33:2188–91.
Besser RE, Griffin PM. Escherichia coli o157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease. Annu Rev Med. 1999;50:355–67.
Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res. 2001;50:163–71.
Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology. 2012;217:195–203.
Kumar V, Abbas A, Aster J. Robbins basic pathology. 9th ed. Philadelphia: Elsevier Saunders; 2013.
Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic–uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930–6.
Panos GZ, Betsi GI, Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther. 2006;24:731–42.
Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, et al. Eculizumab in severe Shiga-Toxin–Associated HUS. N Engl J Med. 2011;364:2561–3.
Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256–64.
Schuller Y, Hollak CEM, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review. Orphanet J Rare Dis BioMed Central. 2015;10:92.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors PB, RB, and JP declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies/tests involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from the parent(s) for all medical procedures described in this report, with the exception of the autopsy, which was performed under the jurisdiction of the medical examiner’s office. The informed consent included permission for specimen testing and record review for teaching and research purposes.
Support
No sources of financial support.
Disclaimers
None.
Rights and permissions
About this article
Cite this article
Bystrom, P.V., Beck, R.J. & Prahlow, J.A. Hemolytic uremic syndrome caused by E. coli O157 infection. Forensic Sci Med Pathol 13, 240–244 (2017). https://doi.org/10.1007/s12024-017-9852-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12024-017-9852-y